Menu
Search
|

Menu

Close
X

Marinus Pharmaceuticals Inc MRNS.OQ (NASDAQ Stock Exchange Global Market)

5.72 USD
-0.18 (-3.05%)
As of Oct 19
chart
Previous Close 5.90
Open 5.95
Volume 101,914
3m Avg Volume 195,277
Today’s High 6.02
Today’s Low 5.64
52 Week High 10.54
52 Week Low 3.31
Shares Outstanding (mil) 40.53
Market Capitalization (mil) 298.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.384
FY17
-0.818
FY16
-1.469
FY15
-1.657
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
--
6.55
Price to Book (MRQ)
vs sector
6.63
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-79.32
12.83
Return on Equity (TTM)
vs sector
-79.63
14.95

EXECUTIVE LEADERSHIP

Christopher Cashman
Chairman of the Board, President, Chief Executive Officer, Since 2012
Salary: $484,100.00
Bonus: $257,000.00
Lorianne Masuoka
Chief Medical Officer, Since 2017
Salary: $266,146.00
Bonus: $96,000.00
Scott Braunstein
Independent Director, Since 2018
Salary: --
Bonus: --
Enrique Carrazana
Independent Director, Since 2013
Salary: --
Bonus: --
Michael Dougherty
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

170 N Radnor Chester Rd Ste 250
RADNOR   PA   19087-5279

Phone: +1484.8014670

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

SPONSORED STORIES